Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations

@inproceedings{Willmann2018IntegratedPP,
  title={Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations},
  author={Stefan Willmann and Liping Zhang and Matthias Frede and Dagmar Kubitza and Wolfgang Mueck and Stephan Schmidt and Alexander Solms and Xiaoyu Yan and Dirk Garmann},
  booktitle={CPT: pharmacometrics & systems pharmacology},
  year={2018}
}
The population pharmacokinetics (PK) of rivaroxaban have been evaluated in several population-specific models. We developed an integrated population PK model using pooled data from 4,918 patients in 7 clinical trials across all approved indications. Effects of gender, age, and weight on apparent clearance (CL/F) and apparent volume of distribution (V/F), renal function, and comedication on CL/F, and relative bioavailability as a function of dose (F) were analyzed. Virtual subpopulations for… CONTINUE READING
3
Twitter Mentions

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Population pharmacokinetics of edoxaban in patients with nonvalvular atrial fibrillation in the ENGAGE AF-TIMI 48 study, a phase III clinical trial

Krekels, E.H
  • Clin. Pharmacokinet
  • 2016

Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism–the Hokusai-VTE phase 3 study

R Niebecker
  • Br. J. Clin. Pharmacol
  • 2015

results from ROCKET AF

Girgis, I. G. et al. Population pharmacokinetics, pharmacodynamics of rivaroxaban in patients with non-valvular atria fibrillation
  • J. Clin. Pharmacol. 54, 917–927
  • 2014

The effect of food on the absorption and pharmacokinetics of rivaroxaban.

  • International journal of clinical pharmacology and therapeutics
  • 2013
VIEW 1 EXCERPT